With clinical trials becoming a bit more complicated, and with new processes of running genomic related reports during the time frame, it is getting to be a bit of a complicated issue, thus now there are services that will help find the appropriate candidates for the trials.  No longer is it perhaps just one issue they are looking for, as of course drugs today are addressing more than one issue as well.  There appears to be an entire new crop of businesses that have the data bases and facilities to help locate individuals for participants.  As always, this has to be an opt in basis to be notified.

As an interesting side note, yesterday I had posted on the face lift for the Microsoft HealthVault and one vendor working with the Vault does exactly this, but a little different process in the fact that it can mine the personal health records and find various individuals for participation, again on an opt in basis from the consumer.  Personal Health Records online stand to also be an option and on the other hand this also may serve to expand the use of Personal Health Records online.  BD 

16-Sep-2008 - Patient recruitment specialist Acurian has hit a major milestone in its business, with more than half of the entire US population of type 2 diabetics now opted into its database. That means the company now has around 8 million of the estimated 16 million diagnosed type 2 or adult-onset diabetics on its books. Overall, the company has a database of around 40 million patients.

According to Malcolm, for trial sponsors it is no longer just an issue of finding a diabetic with a certain level of haemoglobin A1c, a commonly-used marker for glucose control.

"Compared to just a few years ago, the diabetes protocols we see today are not garden variety," continued Malcolm. "Trial sponsors are aggressively competing for treatment naive, metformin-only, or diabetics with specific co-morbidities such as obesity.”

Competition intensifying for diabetes subjects; Acurian

0 comments :

Post a Comment

 
Top
Google Analytics Alternative